<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743793</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN063ST</org_study_id>
    <secondary_id>UM1AI109565</secondary_id>
    <nct_id>NCT02743793</nct_id>
  </id_info>
  <brief_title>A Cohort Study of Operationally Tolerant Allograft Recipients</brief_title>
  <acronym>ALLTOL</acronym>
  <official_title>A Prospective Cohort Study of Operationally Tolerant Allograft Recipients (ITN063ST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho Federal Systems Division, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ&#xD;
      transplant recipients to prevent their bodies from rejecting the new organ. Some organ&#xD;
      transplant recipients can stop taking anti-rejection medicines without rejecting their&#xD;
      transplanted organ (this is called 'tolerance'). The purpose of this study will collect&#xD;
      samples and data from 'tolerant' liver or kidney transplant recipients in order to find out:&#xD;
&#xD;
      The purpose of this study is to collect samples and data in order to find out:&#xD;
&#xD;
        -  How long liver or kidney transplant recipients can remain tolerant;&#xD;
&#xD;
        -  What happens in the tolerant recipient's body over time; and&#xD;
&#xD;
        -  If there are patterns in the body that are linked to tolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, observational study in which operationally tolerant&#xD;
      recipients of liver or kidney allografts will be followed longitudinally, with annual&#xD;
      collections of clinical data and biological samples. All participants will be followed for&#xD;
      the duration of the study, regardless of changes in their tolerance status.&#xD;
&#xD;
      Participants will be recruited by three main pathways:&#xD;
&#xD;
        1. Tolerant participants from current and past Immune Tolerance Network (ITN) trials,&#xD;
           including those who have already completed trial participation and those who are&#xD;
           anticipated to complete trial participation,&#xD;
&#xD;
        2. Tolerant participants referred by ITN affiliated investigators, academic and community&#xD;
           transplant physicians and directly through outreach to transplant affinity groups such&#xD;
           as the National Kidney Foundation (NKF), and&#xD;
&#xD;
        3. Tolerant participants from the general transplant community who are reachable through&#xD;
           general contact channels such as the ITN website, word-of-mouth referrals from existing&#xD;
           participants, and social media.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID-19 pandemic and potential risks to study participants and study staff.&#xD;
  </why_stopped>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Loss of Operational Tolerance</measure>
    <time_frame>From operational tolerance to ITN063ST study completion, assessed up to 60 months</time_frame>
    <description>A participant is considered to have operational tolerance if they are off all immunosuppression medication while continuing to have stable allograft function and no rejection. For these participants, the date of operational tolerance is considered as 52 weeks from the participant's last documented dose of immunosuppression. A participant will be considered to have lost operational tolerance if they experience rejection, have loss of stable allograft function (in the absence of confounding factors), or restart immunosuppression. The endpoint was analyzed using Kaplan-Meier survival estimate and associated two-sided 95% confidence interval, using a delayed-entry model with left-truncation of survival times by censoring the time from achieving operational tolerance at the time of study enrollment. The survival estimate is at the time of the last of event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Development of Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA)</measure>
    <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
    <description>Time to development of either:&#xD;
de novo HLA antibodies (anti-HLA Ab) post-transplant. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen; OR&#xD;
Donor Specific Antibodies (DSA), a newly developed alloantibody that is against the donor organ.&#xD;
Alloantibodies are important mediators of acute and chronic rejection.&#xD;
**These data are not yet available.**</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Biopsy-Proven or Clinical Acute Rejection, Steroid Resistant Rejection and/or Chronic Rejection</measure>
    <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
    <description>Number of participants with acute rejection, steroid resistant rejection and/or chronic rejection.&#xD;
Criteria employed for acute and chronic rejection: Banff guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Loss, Not Including Death With a Functioning Graft</measure>
    <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
    <description>A participant is considered to have graft loss when the participant is retransplanted with another donor kidney, relisted for transplantation, or dies with a non-functioning graft.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Operationally Tolerant Kidney or Liver Allograft Recipients</arm_group_label>
    <description>Operational tolerance at baseline is defined as:&#xD;
An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;&#xD;
No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and&#xD;
Normal and stable allograft function at screening visit defined as-&#xD;
For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)&#xD;
For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) &gt; 45 ml/min/1.73 m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <arm_group_label>Operationally Tolerant Kidney or Liver Allograft Recipients</arm_group_label>
    <other_name>Phlebotomy</other_name>
    <other_name>Venesection</other_name>
    <other_name>Venipuncture</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Operationally tolerant recipients of liver or kidney allografts&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient of single organ liver or kidney allograft from a living or deceased donor;&#xD;
&#xD;
          -  At screening, operationally tolerant, as defined by:&#xD;
&#xD;
               -  Absence of any immunosuppressive therapy for ≥52 weeks prior to the screening&#xD;
                  visit, and&#xD;
&#xD;
               -  No evidence of allograft rejection in the 52 weeks prior to the screening visit,&#xD;
                  based on the allograft recipient's medical history.&#xD;
&#xD;
          -  Normal allograft function, defined as:&#xD;
&#xD;
               -  For liver transplant recipients: Liver function tests (ALT, GGT) both less than&#xD;
                  or equal to the upper limit of normal (ULN); and,&#xD;
&#xD;
               -  For kidney transplant recipients: Serum creatinine value corresponds to an&#xD;
                  estimated GFR &gt; 45 ml/min/1.73 m^2.&#xD;
&#xD;
          -  Receiving regular follow-up for a kidney or liver transplant by a local physician:&#xD;
&#xD;
             --Participants must be willing to allow the study team to contact and share medical&#xD;
             information with this local physician.&#xD;
&#xD;
          -  Ability to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current malignancy requiring recent surgery, ongoing chemotherapy, or radiation;&#xD;
&#xD;
          -  Transplant of another organ;&#xD;
&#xD;
          -  Current drug or alcohol dependency;&#xD;
&#xD;
          -  Any medical condition that in the opinion of the principal investigator would&#xD;
             interfere with safe completion of the trial; and&#xD;
&#xD;
          -  Inability to comply with the study visit schedule and required assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sindhu Chandran, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Immune Tolerance Network (ITN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Memorial Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburg of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.immunetolerance.org/</url>
    <description>Immune Tolerance Network (ITN)</description>
  </link>
  <link>
    <url>http://www.alltol.org</url>
    <description>ITN ALLTOL Study website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <results_first_submitted>June 11, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>single organ liver or kidney allograft</keyword>
  <keyword>operationally tolerant allograft recipients</keyword>
  <keyword>longitudinal follow-up</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.</ipd_description>
    <ipd_time_frame>On average, within 24 months after database lock for the trial.</ipd_time_frame>
    <ipd_access_criteria>Open access.</ipd_access_criteria>
    <ipd_url>https://www.immport.org/home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02743793/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02743793/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>41 tolerant kidney and liver participants were recruited from June 2016 through February 2020 along three main pathways 1) from current and past Immune Tolerance Network (ITN) trials, 2) by ITN affiliation investigators, academic community transplant physicians, and through outreach to transplant affinity groups, and 3) from the general transplant community through media channels.</recruitment_details>
      <pre_assignment_details>Informed consent was obtained from potentially eligible individuals who underwent a screening visit to determine eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enrolled, Not Eligible</title>
          <description>These participants were consented and enrolled into the study, but did not meet eligibility criteria.</description>
        </group>
        <group group_id="P2">
          <title>Accrued</title>
          <description>These participations met all eligibility criteria and completed at least one mechanistic sample collection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Primary Care Physician</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel/remote visits could not be performed at nursing facility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study stopped due to COVID-19 pandemic</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled, Not Eligible</title>
          <description>These participants were consented and enrolled into the study, but did not meet eligibility criteria.</description>
        </group>
        <group group_id="B2">
          <title>Accrued</title>
          <description>These participations met all eligibility criteria and completed at least one mechanistic sample collection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="29.4"/>
                    <measurement group_id="B2" value="40" spread="24.3"/>
                    <measurement group_id="B3" value="40" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of operational tolerance at time of enrollment.</title>
          <description>To be considered for the trial, the participant had to have established operational tolerance. A participant is considered to have operational tolerance if they are off all immunosuppression medication while continuing to have stable allograft function and no rejection. For these participants, the date of operational tolerance is considered as 52 weeks from the participant's last documented dose of immunosuppression.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="5.07"/>
                    <measurement group_id="B2" value="8.1" spread="7.53"/>
                    <measurement group_id="B3" value="8.1" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT)</title>
          <description>The ALT result from the screening visit. The measure is only relevant to liver recipients. The normal range is 7-41 U/L.</description>
          <population>Number of participants analyzed based on number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="NA">Only one participant had an ALT result available.</measurement>
                    <measurement group_id="B2" value="24.5" spread="11.98"/>
                    <measurement group_id="B3" value="26.1" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gamma glutamyltransferase (GGT)</title>
          <description>The GGT result from the screening visit. The measure is only relevant to liver recipients. The normal range is 9-58 U/L.</description>
          <population>Number of participants analyzed based on number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="NA">Only one participant had a GGT result available.</measurement>
                    <measurement group_id="B2" value="32.4" spread="49.33"/>
                    <measurement group_id="B3" value="31.8" spread="48.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <description>The creatinine result from the screening visit. The measure is only relevant to kidney recipients. The normal range for creatinine is 0.5-0.9 mg/dL for females and 0.6-1.2 mg/dL for males.</description>
          <population>Number of participants analyzed based on number of participants with data available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="NA">Only one participant had a creatinine result available.</measurement>
                    <measurement group_id="B2" value="1.3" spread="0.48"/>
                    <measurement group_id="B3" value="1.4" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Loss of Operational Tolerance</title>
        <description>A participant is considered to have operational tolerance if they are off all immunosuppression medication while continuing to have stable allograft function and no rejection. For these participants, the date of operational tolerance is considered as 52 weeks from the participant's last documented dose of immunosuppression. A participant will be considered to have lost operational tolerance if they experience rejection, have loss of stable allograft function (in the absence of confounding factors), or restart immunosuppression. The endpoint was analyzed using Kaplan-Meier survival estimate and associated two-sided 95% confidence interval, using a delayed-entry model with left-truncation of survival times by censoring the time from achieving operational tolerance at the time of study enrollment. The survival estimate is at the time of the last of event.</description>
        <time_frame>From operational tolerance to ITN063ST study completion, assessed up to 60 months</time_frame>
        <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Accrued</title>
            <description>These participants met all eligibility criteria and completed at least one mechanistic sample collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Operational Tolerance</title>
          <description>A participant is considered to have operational tolerance if they are off all immunosuppression medication while continuing to have stable allograft function and no rejection. For these participants, the date of operational tolerance is considered as 52 weeks from the participant's last documented dose of immunosuppression. A participant will be considered to have lost operational tolerance if they experience rejection, have loss of stable allograft function (in the absence of confounding factors), or restart immunosuppression. The endpoint was analyzed using Kaplan-Meier survival estimate and associated two-sided 95% confidence interval, using a delayed-entry model with left-truncation of survival times by censoring the time from achieving operational tolerance at the time of study enrollment. The survival estimate is at the time of the last of event.</description>
          <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
          <units>Years to loss of operational tolerance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No test was performed.</non_inferiority_desc>
            <param_type>Kaplan-Meier survival estimate</param_type>
            <param_value>64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.3</ci_lower_limit>
            <ci_upper_limit>87.9</ci_upper_limit>
            <estimate_desc>Percent of participants that remained tolerant during study participation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Development of Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA)</title>
        <description>Time to development of either:&#xD;
de novo HLA antibodies (anti-HLA Ab) post-transplant. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen; OR&#xD;
Donor Specific Antibodies (DSA), a newly developed alloantibody that is against the donor organ.&#xD;
Alloantibodies are important mediators of acute and chronic rejection.&#xD;
**These data are not yet available.**</description>
        <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Biopsy-Proven or Clinical Acute Rejection, Steroid Resistant Rejection and/or Chronic Rejection</title>
        <description>Number of participants with acute rejection, steroid resistant rejection and/or chronic rejection.&#xD;
Criteria employed for acute and chronic rejection: Banff guidelines.</description>
        <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
        <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Accrued</title>
            <description>These participants met all eligibility criteria and completed at least one mechanistic sample collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biopsy-Proven or Clinical Acute Rejection, Steroid Resistant Rejection and/or Chronic Rejection</title>
          <description>Number of participants with acute rejection, steroid resistant rejection and/or chronic rejection.&#xD;
Criteria employed for acute and chronic rejection: Banff guidelines.</description>
          <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Loss, Not Including Death With a Functioning Graft</title>
        <description>A participant is considered to have graft loss when the participant is retransplanted with another donor kidney, relisted for transplantation, or dies with a non-functioning graft.</description>
        <time_frame>Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)</time_frame>
        <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Accrued</title>
            <description>These participants met all eligibility criteria and completed at least one mechanistic sample collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Loss, Not Including Death With a Functioning Graft</title>
          <description>A participant is considered to have graft loss when the participant is retransplanted with another donor kidney, relisted for transplantation, or dies with a non-functioning graft.</description>
          <population>Participants who met all eligibility criteria and completed at least one mechanistic sample collection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3.7 years.</time_frame>
      <desc>Only adverse events that met serious criteria were collected for this study.&#xD;
Inclusion: A serious adverse event (SAE) that occurred:&#xD;
within 24 hours after a protocol-mandated blood draw, or&#xD;
if an SAE occurred more than 24 hours after a protocol-mandated blood draw and was deemed as a possibly or definitely association with a protocol-mandated blood draw.&#xD;
Participants in the &quot;Enrolled, Not Eligible&quot; Arm/Group did not undergo any protocol mandated blood draws and are not represented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Enrolled, Not Eligible</title>
          <description>These participants were consented and enrolled into the study, but did not meet eligibility criteria. Only adverse events meeting serious criteria were collected for this study. A SAE is defined as &quot;any adverse event that meets on or more serious criterion and occurs within 24 hours of the protocol mandated blood draw for research specimens. Those in the &quot;Enrolled, Not Eligible&quot; Arm/Group did not undergo any protocol mandated blood draws and so no adverse events will be reported for this Arm/Group.</description>
        </group>
        <group group_id="E2">
          <title>Accrued</title>
          <description>Accrued participations met all eligibility criteria and completed at least one mechanistic sample collection. Only adverse events meeting serious criteria were collected for this study. An SAE is defined as &quot;any adverse event that meets one or more serious criterion and occurs within 24 hours of the protocol mandated blood draw for research specimens&quot;.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study team ended the study early due to the COVID-19 pandemic on March 24, 2020.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Operations Program</name_or_title>
      <organization>DAIT/NIAID</organization>
      <phone>13015947669</phone>
      <email>DAITClinicalTrialsGov@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

